The single-shot drug Nirsevimab, which can prevent the Respiratory Syncytial Virus (RSV) in infants, is short in supply. The Children’s Hospital Association says this will limit its impact this respiratory disease season. This drug, marketed as Beyfortus, cuts the risk of RSV-related hospitalization in infants by about 80% and, though supply constraints mean vulnerable infants are the priority, demand exceeds supply. The manufacturer AstraZeneca apparently underestimated the demand for the drug, despite its potential to prevent RSV.
Microsoft to Offer Rewards Up to $30,000 for AI Vulnerabilities
Microsoft has launched a bug bounty program offering up to $30,000 for identifying critical AI vulnerabilities in Dynamics 365 and Power Platform. The initiative, part
